Clinical perspective of afatinib in non-small cell lung cancer
Authors:
- Quan ZhuQZQuan Zhu
- Lingjun ZhuLZLingjun Zhu
- Dong PeiDPDong Pei
- Yiqian LiuYLYiqian Liu
- Yongmei YinYYYongmei Yin
- Martin SchulerMSMartin Schuler
- Yongqian ShuYSYongqian Shu
- 1 August 2013
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 81 (2) , 155-161
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospectsCancer Treatment Reviews, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Irreversible Protein Kinase InhibitorsCurrent Medicinal Chemistry, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models withEGFRandERBB2Mutations that Are Resistant to GefitinibCancer Research, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Structural Bioinformatics-Based Design of Selective, Irreversible Kinase InhibitorsScience, 2005
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProceedings of the National Academy of Sciences, 2005